Comparative pharmacology of selective serotonin re-uptake inhibitors (SSRIs)
- 1 January 1993
- journal article
- research article
- Published by Taylor & Francis in Nordic Journal of Psychiatry
- Vol. 47 (sup30) , 5-12
- https://doi.org/10.3109/08039489309104119
Abstract
Tricyclic antidepressants (TCAs) affect a series of neurotransmitter functions. The uptake of noradrenaline (NA) and serotonin (5-HT) is inhibited to a varying degree. Many of the TCAs potently inhibit a series of neurotransmitter receptors. A series of newer antidepressants preferentially increases 5-HT transmission by inhibiting 5-HT uptake. Selective serotonin re-uptake inhibitors (SSRIs) are those which have a high potency ratio of 5-HT-uptake inhibition as compared to NA-uptake inhibition, together with slight or no effect on other uptake mechanisms, neurotransmitter receptors, enzymes, etc. The marketed SSRIs, citalopram, fluoxetine, fluvoxamine, paroxetine, and sertraline all fulfil the above-mentioned criteria. Paroxetine is the most potent 5-HT-uptake inhibitor, whereas citalopram is the most selective. In general, the rank order of selectivity is equal in in vitro studies, in biochemical in vivo studies and in behavioural studies. Potency and selectivity for 5-HT uptake do not coincide. In contrast to TCAs, most of which inhibit receptors for acetylcholine, histamine, NA, 5-HT or DA, most SSRIs neither bind to nor inhibit these receptors. Likewise, monoamine oxidase (MAO) is not inhibited by these drugs. Citalopram, fluoxetine and sertraline are metabolized to compounds possessing similar properties as the parent drugs, whereas this is not the case with the metabolites of fluvoxamine and paroxetine. Upon repeated administration the potency and selectivity of SSRIs are maintained. Although repeated treatment with TCAs and electroconvulsive shocks leads to changes in receptor number and pharmacological responsiveness, e.g. down-regulation of β-adrenoceptors and down-regulation of 5-HT2-mediated function, no consistent changes are seen after prolonged treatment with SSRIs. Since SSRIs show antidepressant effect, this receptor regulation seems not to be a prerequisite for clinical antidepressant activity.Keywords
This publication has 24 references indexed in Scilit:
- Cloning of a Serotonin Transporter Affected by AntidepressantsScience, 1991
- Affinity modulation of [3H]imipramine, [3H]paroxetine and [3H]citalopram binding to the 5-HT transporter from brain and plateletsEuropean Journal of Pharmacology: Molecular Pharmacology, 1991
- [3H]Citalopram Binding to Brain and Platelet Membranes of Human and RatJournal of Neurochemistry, 1991
- Biochemical and Pharmacological Characterization of [3H]GBR 12935 Binding In Vitro to Rat Striatal Membranes: Labeling of the Dopamine Uptake ComplexJournal of Neurochemistry, 1987
- SEROTONIN‐SELECTIVE ANTIDEPRESSANTS.Acta Pharmacologica et Toxicologica, 1985
- High affinity binding of [3H]paroxetine and [3H]imipramine to human platelet membranesEuropean Journal of Pharmacology, 1983
- Specific high affinity [3H]imipramine binding sites in rat lung are associated with a non-neuronal uptake site for serotoninEuropean Journal of Pharmacology, 1983
- High-affinity [3H]desipramine binding in the peripheral and central nervous system: A specific site associated with the neuronal uptake of noradrenalineEuropean Journal of Pharmacology, 1982
- Citalopram — Pharmacological profile of a specific serotonin uptake inhibitor with antidepressant activityProgress in Neuro-Psychopharmacology and Biological Psychiatry, 1982
- High-affinity [3H]DMI binding is associated with neuronal noradrenaline uptake in the periphery and the central nervous systemEuropean Journal of Pharmacology, 1981